Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity

Seminars in Arthritis and Rheumatism

Volumn 27, Issue 5, 1998, Pages 277-292

  Van Ede, A E ^a   Laan, R F J M ^a   Blom, H J ^a   De Abreu, R A ^a   Van de Putte, L B A ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Mechanism of action; Methotrexate; Rheumatoid arthritis; Toxicity

Indexed keywords

ADENOSINE; FOLIC ACID; FOLINIC ACID; HOMOCYSTEINE; METHIONINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; POLYAMINE; PROBENECID; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FOLATE METABOLISM; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; LEUKOPENIA; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; PURINE METABOLISM; PYRIMIDINE METABOLISM; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS; THROMBOCYTOPENIA;

EID: 0031950185     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(98)80049-8     Document Type: Article

References (200)

1. Gubner R. August S. Ginsberg V. Therapeutic suppression of tissue reactivity II. Effect of aminopterin in rheumatoid arthritis and psoriasis Am J Med Sci 221 1951 176
2. (editorial) Boerbooms A.M.Th. Methotrexate and rheumatoid arthritis Clin Rheumatol 4 1985 378 388
3. Weinblatt M.E. Coblyn J.S. Fox D.A. Fraser P.A. Holdsworth D.E. Glass D.N. Trentham D.E. Efficacy of low-dose methotrexate in rheumatoid arthritis N Engl J Med 312 1985 818 822
4. Wilkens R.F. Watson M.A. Methotrexate: A perspective of its use in the treatment of rheumatic diseases J Lab Clin Med 3 1982 314 321
5. Weinblatt M.E. Lee Maier A. Longterm experience with low dose weekly methotrexate in rheumatoid arthritis J Rheumatol 17 suppl 22 1990 33 38
6. Felson D.T. Anderson J.J. Meenan R.E. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses Arthritis Rheum 33 1990 1449 1461
7. Felson D.T. Anderson J.J. Meenan R.F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalyses of published clinical trials Arthritis Rheum 35 1992 1117 1125
8. Wolfe F. Hawley D.J. Cathey M.A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts J Rheumatol 17 1990 994 1002
9. Weinblatt M.E. Kaplan H. Germain B.F. Block S. Solomon S.D. Merriman R.C. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study Arthritis Rheum 37 1994 1492 1498
10. Alarçon G.S. Tracy I.C. Blackburn W.D. Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment Arthritis Rheum 32 1989 671 676
11. McKendry R.J.R. Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis J Rheumatol 20 1993 1850 1856
12. Scully C.J. Anderson C.J. Cannon G.W. Long-term methotrexate therapy for rheumatoid arthritis Semin Arthritis Rheum 20 1991 317 331
13. Schnabel A. Gross W.L. Low-dose methotrexate in rheumatic diseases. Efficacy, side effects, and risk factors for side effects Semin Arthritis Rheum 23 1994 310 327
14. Goodman T.H. Polisson R.P. Methotrexate: Adverse reactions and major toxicities Rheum Dis Clin North Am 20 1994 513 528
15. Weinblatt M.E. Weissman B.N. Holdsworth D.E. Fraser P.A. Maier A.L. Falchuk K.R. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84 month update Arthritis Rheum 35 1992 129 137
16. Buchbinder R. Hall S. Sambrook P.N. Champion G.D. Harkness A. Lewis D. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice J Rheumatol 20 1993 639 644
17. Salaffi F. Carotti M. Sartini A. Cervini C. A prospective study of the long-term efficacy and toxicity of low-dose methotrexate in rheumatoid arthritis Clin Exp Rheumatol 13 1995 23 28
18. Sany J. Anaya J.M. Lussiez V. Couret M. Combe B. Daures J.-P. Treatment of rheumatoid arthritis with methotrexate: A prospective open long-term study of 191 cases J Rheumatol 18 1991 1323 1327
19. Bannwarth B. Labat L. Moride Y. Schaeverbeke T.H. Methotrexate in rheumatoid arthritis. An update Drugs 47 1994 25 50
20. Furst D.E. Erikson N. Clute L. Koehnke R. Burmeister L.F. Kohler J.A. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis J Rheumatol 17 1990 1628 1635
21. Shiroky J.B. Neville C. Esdaile J.M. Choquette D. Zummer M. Hazeltine M. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial Arthritis Rheum 36 1993 795 803
22. Schnabel A. Reinhold-Keller E. Willmann V. Gross W.L. Tolerability of methotrexate starting with 15 or 25 mg/week for rheumatoid arthritis Rheumatol Int 14 1994 33 38
23. van der Put N.M.J. Steegers-Theunissen R.P.M. Frosst P. Trijbels F.J.M. Eskes T.K.A.B. van den Heuvel L.P. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida Lancet 346 1995 1070 1071
24. Frosst P. Blom H.J. Milos R. Goyette P. Sheppard C.A. Matthews R.G. A candidate genetic risk for vascular disease: A common mutation in methylenetetrahydrofolate reductase Nature Genetics 10 1995 111 113
25. Engbersen A.M.T. Franken D.G. Boers G.H.J. Stevens E.M.B. Trijbels F.J.M. Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia Am J Hum Genet 56 1995 142 150
26. Stokstad E.L.R. Jukes T.H. Sulfonamides and folic acid antagonists: A historical review J Nutr 117 1987 1335 1341
27. Grosflam J. Weinblatt M.E. Methotrexate: Mechanism of action, pharmacokinetics, clinical indications and toxicity Curr Opin Rheumatol 3 1991 363 368
28. Goldman I.D. Matherly L.H. The cellular pharmacology of methotrexate Pharmacol Ther 28 1985 77 102
29. Norway Refsum H. Extracellular homocysteine as an indicator of methotrexate pharmacodynamics. Analytical methods, in vitro experiments, and clinical studies Doctoral thesis 1990 University of Bergen Bergen, Norway
30. Stone T.W. Simmonds H.A. Purities: Basic and clinical aspects 1991 Kluwer Dordrecht
31. Barankiewicz J. Ronlov G. Jimenez R. Gruber H.E. Selective adenosine release from human B but not T lymphoid cell line J Biol Chem 265 1990 15738 15743
32. Barankiewicz J. Jimenez R. Ronlov G. Magill M. Gruber H.E. Alteration of purine metabolism by AICA-riboside in human B lymphoblasts Arch Biochem Biophys 282 1990 377 385
33. Cronstein B.N. Hirschhorn R. Adenosine and host defence: Modulation through metabolism and receptor-mediated mechanisms Williams M. Adenosine and adenosine receptors 1990 The Humana Press Clifton, NJ 475 500
34. Refsum H. Helfand S. Ureland P.M. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low-dose methotrexate treatment Pharmacol Ther 46 1989 510 520
35. Chu R.C. Hall C.A. The total serum homocysteine as an indicator of vitamin B12 and folate status Am J Clin Pathol 90 1988 446 449
36. Kang S.S. Wong P.W.K. Norusis M. Homocysteinemia due to folate deficiency Metabolism 3 1987 458 462
37. Stabler S.P. Marcell P.D. Podell E.R. Allen R.H. Savage D.G. Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamine or folate deficiency detected by capillary gas chromatography-massspectrometry J Clin Invest 81 1988 466 474
38. Ueland P.M. Refsum H. Svardal A.M. Djurhuus R. Helfand S. Pertubation of homocysteine metabolism by pharmacological agents in experimental and clinical use Aarbakke J. Chiang P.K. Koeffler H.P. Tumor cells differentiation. Biology and pharmacology 1987 The Humana Press Clifton, NJ 269 278
39. Ueland P.M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase Phanmacol Rev 34 1982 223 253
40. Cantoni G.L. The centrality of S-adenosyl-homocysteinase in the regulation of the biological utilization of S-adenosylmethionine Borchardt R.T. Creveling C.R. Ueland P.M. Biological Methylafon and Drug Design. Experimental and Clinical Roles of S-adenosyl-methionine 1986 The Humana Press Clifton, NJ 227 238
41. Finkelstein J.D. Methionine metabolism in mammals J Nutr Biochem 1 1990 228 237
42. Pegg A.E. S-adenosylmethionine decarboxylase: A brief review Cell Biochem Funct 2 1984 11 15
43. Tabor C.W. Tabor H. Polyamines Ann Rev Biochem 53 1984 749 790
44. Pasquali J.L. Mamont P.S. Weryha A. Knapp A.M. Blervaque A. Siat M. Immunosuppressive effects of (2R,5R)-6-heptyne-2,5-diamine, an inhibitor of polyaminesynthesis. I. Effects on mitogen-induced immunoglobulin production in human culturedd lymphocytes Clin Exp Immunol 72 1988 141 144
45. Yukioka K. Otani S. Matsui-Yuasa I. Shibata T. Nishizawa Y. Morii H. Polyamine biosynthesis is necessary for interleukin-2-dependent proliferation but not for interleukin-2 production of high-affinity interieukin-2receptor expression J Biochem 102 1987 1469 1476
46. Bowlin T.L. McKown B.J. Babcock G.F. Sunkara P.S. Intracellular polyamine biosynthesis is required for interleukin-2 responsiveness during lymfocyte mitogenesis Cell Immunol 106 1987 420 427
47. Furst D.E. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis Br J Rheumatol 34 suppl 2 1995 20 25
48. Chabner B.A. Allegra A. Curt C. Clendein N.J. Baram J. Koizumi S. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76 1985 907 912
49. Baugh C.M. Krumdieck C.L. Nair M.G. Polygammaglutamyl metabolites of methotrexate Biochem Biophys Res Commun 52 1973 27 34
50. Jacobs S.A. Derr C.J. Johns D.G. Accumulation of methotrexate diglutamate in human liver during methotrexate therapy Biochem Pharmacol 26 1977 2310 2313
51. Rosenblatt D.S. Whitehead V.M. Vera N. Pottier A. Dupont M. Vuehich M.J. Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells Mol Pharmacol 14 1978 1143 1147
52. Koizumi S. Curt G.A. Fine R.L. Griffin J.D. Chabner B.A. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow J Clin Invest 75 1985 1008 1014
53. Allegra C.J. Drake J.C. Jolivet J. Chabner B.A. Inhibition of folate-dependent enzymes by methotrexatepolyglutamates Goldman I.D. Proceedings of the second workshop on folyl and antifolyl polyglutamates 1984 Praeger Westport, CT 348 359
54. Baggott J.E. Vaughn W.H. Hudson B.B. Inhibition of 5-aminoimidazol-4-carboximide ribotide transformylase, adenosine deaminase, and 5′-adenylate deaminase by polyglutamates ofmethotrexate and oxidized folates and by 5′aminomidazol-4-carboximide riboside and ribotide Biochem J 236 1986 193 200
55. Bunni M. Doig M.T. Donato H. Kesavan V. Priest D.G. Role of methylenetetrahydrofolate depletion in methotrexate-mediated cellular thymidilate synthesis inhibition in cultured L 1210 cells Cancer Res 48 1988 3398 3404
56. Baram J. Allegra C.J. Fine R.L. Chabner B.A. Effects of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow J Clin Invest 79 1987 692 697
57. Morgan S.L. Baggott J.E. Altz-Smith M. Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy Arthritis Rheum 30 1987 1348 1356
58. (abstract) Hine R.J. Alarcon G.S. Koopmans W.J. Morgan S.L. Baggott J.E. Clegg D.O. Serum folate (FA) levels of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) or other disease-modifying antirheumatic drugs(DMARDs) Arthritis Rheum 33 Suppl 5 1990 S60
59. Chu E. Drake J.C. Boatman D. Baram J. Allegras C.J. Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cells lines and normal human myeloid progenitor cells J Biol Chem 265 1990 8470 8478
60. Allegra C.J. Chabner B.A. Drake J.C. Lutz R. Rodbard D. Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate poly-glutamates J Biol Chem 260 1985 9720 9726
61. Allegra C.J. Drake J.C. Jolivet J. Chabner B.A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates Proc Natl Acad Sci USA 82 1985 4881 4885
62. Allegra C.J. Hoang K. Chao Yeh G. Drake J.C. Baram J. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 cells as a principle mode of metabolic inhibition by methotrexate J Biol Chem 262 1987 13520 13526
63. Scanlon K.J. Berkowitz K. Pallai M.E. Waxman S. Inhibition of methionine transport by methotrexate in mitogen stimulated human lymphocytes Cancer Treat Rep 67 1983 631 639
64. Jeurissen M.E.C. Boerbooms A.M.T.H. van de Putte L.B.A. Methotrexate therapy in connective tissue diseases: A review of the literature Neth J Med 35 1989 44 58
65. Boerbooms A.M.T. Methotrexate and rheumatoid arthritis Clin Rheumatol 4 1985 387 388
66. Boerbooms A.M.T. Jeurissen M.E.C. van de Putte L.B.A. Methotrexate in refractory rheumatoid arthritis Clin Rheumatol 7 1988 249 256
67. Jeurissen M.E.C. Boerbooms A.M.T.H. van de Putte L.B.A. Doesburg W.H. Mulder J. Rasker J.J. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial Arthritis Rheum 34 1991 761 772
68. Williams H.L. Wilkins R.F. Samuelson C.O. Alarçon G.S. Guttadauria M. Yarboro C. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial Arthritis Rheum 28 1985 721 730
69. Kremer J.M. Phelps C.T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months Arthritis Rheum 35 1992 138 145
70. (abstract) Tracy I.C. Strand G. Singh K.P. Alargon G.S. A 10 year follow-up of a large methotrexate-treated cohort of rheumatoid arthritis patients Arthritis Rheum 35 Suppl 9 1992 S147/B182
71. Hanrahan P.S. Scrivens G.A. Russell A.S. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy, and radiological progression Br J Rheumatol 28 1989 147 153
72. Weinblatt M.E. Efficacy of methotrexate in rheumatoid arthritis Br J Rheumatol 34 suppl 2 1995 43 48
73. Jeurissen M.E.C. Boerbooms A.M.T.H. van de Putte L.B.A. Doesburg W.H. Lemmens A.M. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: A randomized, double-blind study Ann Intern Med 114 1991 999 1004
74. Weinblatt M.E. Polisson R. Blotner S.D. Sosman J.L. Aliabadi P. Baker N. The effect of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auronofin Arthritis Rheum 36 1993 613 619
75. Weinblatt M.E. Trentham D.E. Fraser P.A. Holdsworth D.E. Falchuk K.R. Weisman B.N. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis Arthritis Rheum 31 1988 167 175
76. Reykdal S. Steinsson K. Sigurjonsson Brekkan A. Methotrexate treatment of rheumatoid arthritis: Effects on radiological progression Scand J Rheumatol 18 1989 221 226
77. Sany J. Kaliski S. Couret M. Cuchacovich M. Daures J. Radiologic progression during intramuscular methotrexate treatment of rheumatoid arthritis J Rheumatol 17 1990 1636 1641
78. Hamdy H. McKendry R.J.R. Mierins E. Liver J.A. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. A twenty-four-week controlled clinical trial Arthritis Rheum 30 1987 361 368
79. Kremer J.M. Lee J.K. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after 53 months Arthritis Rheum 31 1988 577 676
80. Alarçon G.S. López-Méndez Walter J. Boerbooms A.M.T. Russell A.S. Furst D.E. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: A meta-analysis J Rheumatol 19 1992 1868 1873
81. Weinblatt M.E. Kaplan H. Germain B.F. Merriman R.C. Solomon S.D. Wall B. Low-dose methotrexate compared with auronofin in adult rheumatoid arthritis. A thirty-six week, double-blind trial Arthritis Rheum 33 1990 330 338
82. Fries J.F. Williams C.A. Ramey D. Bloch D.A. The relative toxicity of disease-modifying antirheumatic drugs Arthritis Rheum 36 1993 297 306
83. Morand E.F. McCloud P.I. Littlejohn G.O. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice J Rheumatol 19 1992 704 708
84. Pincus T. Marcum S.B. Callahan L.F. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices II. Second line drugs and prednisone J Rheumatol 19 1992 1885 1894
85. Girgis L. Conaghan P.G. Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, sulfasalazine, gold, and malarials, and penicillamine Curr Opin Rheumatol 6 1994 252 261
86. Furst D.E. Koehnke R. Burmeister L.F. Kohler J. Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis J Rheumatol 16 1989 313 320
87. Seideman P. Methotrexate. The relationship between dose and clinical effect Br J Rheumatol 32 1993 751 753
88. Weinstein A. Marlowe S. Korn J. Farouhar F. Low-dose methotrexate treatment of rheumatoid arthrits: Long-term observations Am J Med 79 1985 331 337
89. Hanrahan P.S. Russell A.S. Concurrent use of folinic acid and methotrexate in rheumatoid arhtritis J Rheumatol 15 1988 1078 1080
90. van de Putte L.B.A. Boerbooms A.M.T.H. Barrera P. Kerstens P.J.S.M. Jeurissen M.E.C. Methotrexate: anti-inflammatory or immunosuppressive? Clin Exp Rheumatol 11 Suppl 8 1993 S97 S99
91. Segal R. Yason M. Tartakovsky B. Methotrexate: Mechanisms of action in rheumatoid arthritis Semin Arthritis Rheum 20 1990 190 200
92. Furst D.E. Kremer J.M. Methotrexate in rheumatoid arthritis Arthritis Rheum 31 1988 305 314
93. Haraoui B. Pelletier J.P. Cloutier J.M. Faure M.P. Martel-Pelletier J. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs Arthritis Rheum 34 1991 153 163
94. Olsen N.J. Murray L.M. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells Arthritis Rheum 32 1989 378 385
95. Olsen N.J. Callahan L.F. Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 30 1987 481 488
96. Nesher G. Moore T.L. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine Arthritis Rheum 33 1990 954 959
97. Alarçon G.S. Schrohenloher R.E. Bartolucci A.A. Ward J.R. Williams H.J. Koopman W.J. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression Arthritis Rheum 33 1990 1156 1161
98. O'Callaghan J.W. Forrest M.J. Brooks P.M. Inhibition of neutrophil chemotaxis in methotrexate treated rheumatoid arthritis patients Rheumatol Int 8 1988 41 45
99. (abstract) Kremer J.M. Lawrence D.A. Correlation of immune parameters with clinical and laboratory effects in a prospective cohort of patients with rheumatoid arthritis receivingmethotrexate Arthritis Rheum 35 Suppl. 9 1992 S144/B166
100. Sperling R.I. Benincaso A.I. Anderson R.J. Coblyn J.S. Austen K.F. Weinblatt M.E. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment withmethotrexate Arthritis Rheum 35 1992 376 384
101. Wilke W.S. Mackenzie A.H. Methotrexate therapy in rheumatoid arthritis Drugs 32 1986 103 113
102. (abstract) Wolff R. Asako H. Granger D.N. Adenosine mediates methotrexate-induced attenuation of leukocyte adherence and emigration in postcapillary venules Arthritis Rheum 35 Suppl 9 1992 S35
103. Cronstein B.N. Eberle M.A. Gruber H.E. Levin R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells Proc Natl Acad Sci USA 88 1991 2441 2445
104. Cronstein B.N. Molecular mechanism of methotrexate action in inflammation Inflammation 16 1992 150 162
105. Cronstein B.N. Naime D. Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo modelof inflammation J Clin Invest 92 1993 2675 2682
106. Cronstein B.N. The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanisme Br J Rheumatol 34 suppl 2 1995 30 32
107. Cronstein B.N. Molecular therapeutics. Methotrexate and its mechanism of action Arthritis Rheum 39 1996 1951 1960
108. Kremer J.M. Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis Br J Rheumatol 34 suppl 2 1995 26 29
109. (editorial review) Kremer J.M. Methotrexate update Scand J Rheumatol 25 1996 341 434
110. Hirata S. Matsubara T. Saura R. Tateishi H. Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate Arthritis Rheum 32 1989 1065 1073
111. Anderson P.A. West S.G. O'Dell J.R. Via C.S. Claypool R.G. Kotzin B.L. Weekly pulse tnethotrexate in rheumatoid arthritis: Clinical and immunological effects in a randomized double-blind study Ann Intern Med 103 1985 489 496
112. Wolos J.A. Logan D.E. Bowlin TL. Methylacetylenic putrescine (MAP), an inhibitor of polyamine biosynthesis, prevents the development of collagen-induced arthritis Cell Immunol 125 1990 498 507
113. Yukioka K. Wakitani S. Yukioka M. Polyamine levels in synovial tissue and synovial fluids of patients with rheumatoid arthritis J Rheumatol 19 1992 689 692
114. Furumitsu Y. Yukioka K. Kojima A. Levels of urinary polyamines in patients with rheumatoid arthritis J Rheumatol 20 1993 1661 1665
115. (abstract) Nesher G. Osborn T.H.G. Moore T.L. Lymfocyte polyamine depletion in rheumatoid arthritis patients treated with methotrexate Arthritis Rheum 37 Suppl. 9 1994 S254 s2
116. Kerstens P.J.S.M. Stolk I.N. Boerbooms A.A.M.T. Purine enzymes in rheumatoid arthritis: Possible association with response to azathioprine. A pilot study Ann Rheum Dis 53 1994 608 611
117. Markert M.L. Purine nucleoside phosphorylase deficiency Immunodef Rev 3 1991 45 81
118. Giblett E.R. Ammann A.J. Wara D.W. Sandman R. Diamond L.K. Nucleosidephosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity Lancet i 1975 1010 1013
119. Sandman R. Ammann A.J. Grose C. Wara D.W. Cellular immunodeficiency associated with nucleoside phosphorylase deficiency Clin Immunol Immunopathol 8 1977 247 253
120. Levinson D.J. Chalker D. Arnold W.J. Reduced purine nucleoside phosphorylase activity in preparations of enriched T-lymphocytes from patients with systemic lupus erythematosus J Lab Clin Med 96 1980 562 569
121. Rich K.D. Arnold W.J. Palella T. Fox I.H. Cellular immune deficiency with autoimmune haemolytic anaemia in purine nucleoside phosphorylase deficiency Am J Med 67 1979 172
122. Carpella-de Luca E. Aiuti F. Lucarelli P. A patient with purine nucleoside phosphorylase deficiency, selective T-cell deficiency and autoimmune haemolytic anaemia J Pediatr 93 1978 1000
123. Giblett E.R. Anderson J.E. Cohen F. Pollara B. Meuwissen H.J. Adenosine-deaminase deficiency in two patients with severely impaired immunity Lancet ii 1972 1067 1069
124. Johnson S.M. North M.E. Asherson G.L. Allsop J. Watts R.W.E. Webster A.D.B. Lymphocyte purine 5′-nucleotidase deficiency in primary hypogammaglobulinemia Lancet i 1977 168 170
125. Edwards N.L. Hagilavy D. Cassidy J.T. Fox I.H. Lymphocyte ecto-5′-nucleotidase deficiency in agammaglobulinemia Science 201 1978 628 630
126. Appelboom T.H. Mandelbaum I. Vertongen F. Purine levels in rheumatoid arthritis J Rheumatol 12 1985 1075 1078
127. Marinello E. Carlucci F. Tabucchi A. Leoncini R. Pizzichinini M. Pagani R. The purine nucleotide content of lymphocytes from patients with rheumatoid arthritis Int J Clin Pharmacol Res 14 1994 57 63
128. (abstract) Stolk J. de Koning D. Mulder J. Purine enzyme activities in early rheumatoid arthritis; preliminary results Clin Pheumatol 14 1995 266
129. Kerstens P.J.S.M. Stolk J.N. Boerbooms A.A.M.T. Purine enzymes in rheumatoid arthritis: Possible association with response to azathioprine. A pilot study Ann Rheum Dis 53 1994 608 611
130. (abstract) Kerstens P. Boerbooms A. Lambooy L. De Abreu R. van de Putte L. Association of purine enzyme levels and response to azathioprine in rheumatoid arthritis Arthritis Rheum 35 suppl 9 1992 S200 s2
131. Kerstens P.J.S.M. Stolk J.N. Boerbooms A.A.M.T. De Abreu R.A. van de Putte L.B.A. Purine enzymes in rheumatoid arthritis. A clue to the prediction of the response to azathioprine? Review and hypothesis Clin Exp Rheumatol 13 1995 107 111
132. Kerstens P.J.S.M. Stolk I.N. de Abreu R.A. Lambooy L.H.J. van de Putte L.B.A. Boerbooms A.M.T. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis Arthritis Rheum 1 1995 142 145
133. Asako H. Wolf R.E. Granger D.N. Leukocyte adherence in rat mesenteric venules: Effects of adenosine and methotrexate Gastroenterology 104 1993 31 37
134. Cronstein B.N. Levin R.I. Belanoff J. Weissmann G. Hirschhorn R. Adenosine: An endogenous inhibitor of neutrophil-mediated injury to endothelial cells J Clin Invest 78 1986 760 770
135. Cronstein B.N. Kramer S.B. Weissmann G. Hirschhorn R. Adenosine: A physiological modulator of superoxide anion generation by human neutrophils J Exp Med 158 1983 1160 1177
136. Parmely M.J. Zhou W.W. Edwards C.K. III Borcherding D.R. Silverstein R. Morrison D.C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice againstendotoxin challenge J Immunol 151 1993 389 396
137. Lappin D. Whaley K. Adenosine A2 receptors on human monocytes modulate C2 production Clin Exp Immunol 57 1984 454 460
138. Boerbooms A.M.Th. Kerstens P.J.S.M. van Loenhout J.W.A. Mulder J. van de Putte L.B.A. Infections during low-dose methotrexate treatment in rheumatoid arthritis Semin Arthritis Rheum 24 1995 411 421
139. Wijnands M.J.H. van't Hof M.A. van Leeuwen M.A. van Rijswijk M.H. van de Putte L.B.A. van Riel P.L.C.M. Long-term second-line treatment: A prospective drug survival study Br J Rheumatol 31 1992 253 258
140. Wijands M.J.H. van Riel P.L.C.M. Management of adverse effects of disease-modifying antirheumatic drugs Drug Saf 13 1995 219 227
141. Wijnands M.J.H. van Riel P.L.C.M. Gribnau F.W.J. van de Putte L.B.A. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. A review of the literature Semin Arthritis Rheum 19 1990 337 352
142. Barrera P. Laan R.F.J.M. van Riel P.L.C.M. Dekhuijzen R.P.N. Boerbooms A.M.Th. van de Potte L.B.A. Methotrexate-related pulmonary complications in rheumatoid arthritis Ann Rheum Dis 53 1994 434 439
143. Kerstens P.J.S.M. Boerbooms A.M.T. Jeurissen M.E.C. Fast J.H. Assmann K.J.M. van de Putte L.B.A. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases J Rheumatol 19 1992 867 871
144. Kamen B.A. Nylen P.A. Camitta B.M. Bertino J.R. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug Br J Haematol 49 1981 355 360
145. Jackson R.C. Biological effects of folic acid antagonists with neoplastic activity Pharmacol Ther 25 1984 61 82
146. Andersen L.S. Hansen E.L. Knudsen J.B. Wester J.U. Hansen G.V.O. Hansen T.M. Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: Relation to withdrawal and side effects J Rheumatol 24 1997 830 837
147. (editorial) Morgan S.L. Alarçon G.S. Krumdieck C.L. Folic acid supplementation during methotrexate therapy: It makes sense J Rheumatol 20 1993 929 930
148. Stenger A.A.M.E. Houtman P.M. Bruyn G.A.W. Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate? Ann Rheum Dis 51 1992 1019 1020
149. Kremer J.M. Galivan J. Streckfuss A. Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation ofpolyglutamates Arthritis Rheum 29 1986 832 835
150. Wortmann R.L. Mitchell B.S. Edwards N.L. Fox I.H. Biochemical basis for differential deoxyadenosine toxicity to T and B lymfoblasts: Role for 5′-nucleotidase Proc Natl Acad Sci 75 1979 2434 2437
151. Cohen A. Hirschhorn R. Horowitz S.D. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency Proc Natl Acad Sci 75 1978 472 476
152. Carson D.A. Kaye J. Seegmiller J.E. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: Possible role of nucleoside kinase (s) Proc Natl Acad Sci 74 1977 5677 5681
153. Baggott J.E. Morgan S.L. Ha T.-S. Alarçon G.S. Koopman W.J. Krumdieck C.L. Antifolates in rheumatoid arthritis: A hypothetical mechanism of action Clin Exp Rheum 11 suppl 8 1993 S101 S105
154. Morgan S.L. Baggott J.E. Refsum H. Ueland P.M. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate Pharmacol Ther 50 1991 547 556
155. Ueland P.M. Refsum H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease, and drug therapy J Lab Clin Med 114 1989 473 501
156. Roubenoff R. Dellaripa P. Nadeau M.R. Abnormal homocysteine metabolism in rheumatoid arthritis Arthritis Rheum 40 1997 718 722
157. The Netherlands Haagsma C.J. Combination of sulphasalazine and methotrexate in the treatment of rheumatoid arthritis Doctoral thesis 1997 University of Nijmegen Nijmegen, Netherlands
158. Barak A.J. Tuma D.J. Berkenhauer H.C. Methotrexate hepatotoxicity J Am Coll Nutr 3 1984 93 96
159. Stewart C.F. Evans W.E. Drug-drug interactions with antirheumatic agents: Review of selected clinically important interactions J Rheumatol 17 suppl 22 1990 16 23
160. al-Awadhi A. Dale P. McKendry R.J. Pancytopenia associated with low dose methotrexate therapy. A regional survey J Rheumatol 20 1993 1121 1125
161. Groenendal H. Rampen F.H. Methotrexate and trimethoprim-sulfamethoxazole—a potentially hazardous combination Clin Exp Dermatol 15 1990 358 360
162. Basin K.S. Escalante A. Beardmore T.D. Severe pancytopenia in a patient taking low dose methotrexate and probenecid J Rheumatol 18 1991 609 610
163. Thomas M.H. Gutterman L.A. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole J Rheumatol 13 1986 440 441
164. Jeurissen M.E.C. Boerbooms A.M.T.H. van de Putte L.B.A. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole Ann Intern Med 111 1989 261
165. Maricic M. Davis M. Gall E.P. Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment Arthritis Rheum 29 1986 133 135
166. van Meerten E. Verweij J. Schellens J.H. Antineoplastic agents. Drug interactions of clinical significance Drug Saf 12 1995 168 182
167. Bourke R.S. Cheda G. Bremer A. Watanabe O. Tower D.B. Inhibition of renal tubular transport of methotrexate by probenecid Cancer Res 35 1975 110 116
168. Liegler D.G. Henderson E.S. Hahn M.A. Oliverio V.T. The effect of organic acids on renal clearance of methotrexate in man Clin Pharmacol Ther 10 1969 849 857
169. Tracy T.S. Krohn K. Jones D.R. Bradley J.D. Hall S.D. Brater D.C. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis Eur J Pharmacol 42 1992 121 125
170. Stewart C.F. Fleming R.A. Germain B.E. Seleznick M.J. Evans W.E. Aspirin alters methotrexate disposition in rheumatoid arthritis patients Arthritis Rheum 12 1991 1514 1520
171. Stewart C.F. Fleming R.A. Arkin C.R. Evans W.E. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis Clin Pharmacol Ther 47 1990 540 546
172. Ahern M. Booth J. Loxton A. McCarthy P. Meffin P. Kevat S. Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs J Rheumatol 15 1988 1356 1360
173. Skeith K.J. Russell A.S. Jamali F. Coates J. Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis J Rheumatol 17 1990 1008 1010
174. Tracy T.S. Worster T. Bradley J.D. Greene P.K. Brater D.G. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis Br J Pharmacol 37 1994 453 456
175. Anaya J. Fabre D. Bressolle F. Effect of etodolac on methotrexate phanrracokineties in patients with rheumatoid arthritis J Rheumatol 21 1994 203 208
176. (abstract) Rooney T.W. Furst D.E. Comparison of toxicity in methotrexate (MTX) treated RA patients also taking aspirin or other NSAID Arthritis Rheum 29 suppl 4 1986 S761/C31
177. Baggott J.E. Morgan S.L. Taisun H.A. Vaughn W.H. Hine R.J. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs Biochem J 282 1992 197 202
178. Furst D.E. Clinically important interactions of nonsteroidal antiinflammatory drugs with other medications J Rheumatol 15 1988 58 62
179. Wilske K.R. Healey L.A. Challenging the therapeutic pyramid: A new look at treatment strategies for rheumatoid arthritis J Rheumatol 17 suppl 25 1990 4 7
180. Wilke W.S. Clough J.D. Therapy for rheumatoid arthritis: Combinations of disease-modifying drugs and new paradigms of treatment Semin Arthritis Rheum 21 1991 21 33
181. Huskisson E.C. Combination chemotherapy of rheumatoid arthritis Br J Rheumatol 26 1987 243 244
182. Boers M. Ramsden M. Long-acting drug combinations in rheumatoid arthritis: A formal overview J Rheumatol 18 1991 316 324
183. Paulus H.E. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis Arthritis Rheum 33 1990 113 120
184. Haagsma C.J. van Riel P.L.C.M. Combination of second line antirheumatic drugs, with the emphasis on sulphasalazine and methotrexate Br J Rheumatol 34 suppl 2 1995 104 108
185. (editorial) Furst D.E. Rational disease-modifying anti-rheumatic drug (DMARD) therapy: Is it possible? Br J Rheumatol 35 1996 707 710
186. Fries J.F. Singh G. Lenert L. Furst D.E. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis Arthritis Rheum 33 1990 1611 1619
187. (abstract) Bautista B.B. Boyce E. Koronkowski M. Schumacher H.R. Jr Effects of second line drugs on progression of subcmaneous rheumatoid nodules Arthritis Rheum 35 Suppl 9 1992 R38
188. Combe B. Guttierrez M. Anaya J. Sany J. Possible efficacy of hydroxychloroquine on accelerated nodulosis during methotrexate therapy for rheumatoid arthritis J Rheumatol 20 1993 755 756
189. Fox R.I. Mechanism of action of hydroxychloroquine as an antirheumatic drug Semin Arthritis Rheum 23 suppl 1 1993 82 91
190. Conaghan P.G. Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine Curr Opin Rheumatol 7 1995 167 173
191. Seideman P. Albertioni F. Beck O. Eksborg S. Peterson C. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis Arthritis Rheum 37 1994 830 833
192. Weinblatt M.E. Maier A.L. Coblyn J.S. Low dose leuvorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis. An 8 week randomized placebo controlled trial J Rheumatol 36 1993 795 803
193. Buckley L.M. Vacek P.M. Coopers S.M. Administration of folinic acid after low dose MTX in patients with RA J Rheumatol 17 1990 1158 1162
194. Tishler M. Caspi D. Fishel B. Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients Arthritis Rheum 31 1988 906 908
195. Joyce D.A. Will R.K. Hoffmann D.M. Laing B. Blackboom S.J. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid Ann Rheum Dis 50 1991 913 914
196. Morgan S.L. Baggott J.E. Vaugn W.H. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis Arthritis Rheum 33 1990 9 18
197. Morgan S.L. Baggott J.E. Vaugn W.H. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial Ann Intern Med 121 1994 833 841
198. (abstract) Morgan S.L. Baggott J.E. Vaughn W.H. 5 mg or 50 mg/week of folic acid (FA) supplementation does not alter the efficacy of methotrexate (MTX) treated rheumatoid arthritis (RA) patients Arthritis Rheum 35 suppl 9 1992 R18
199. Dijkmans B.A. Folate supplementation and methotrexate Br J Rheumatol 34 1995 1172 1174
200. (letter) Morgan S.L. Lee J.Y. Alarcdn G.S. Folic acid and methotrexate in rheumatoid arthritis Ann Int Med 124 1996 74